Quality of outcome reporting in phase II studies in pulmonary tuberculosis

Tuberculosis (TB) remains a major killer amongst the infectious diseases. Current treatment involves a four-drug regimen for at least 6 months. New drugs and regimens are required to shorten treatment duration, reduce toxicity and combat drug resistance, but the optimal methodology to define the cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnett, Laura Jayne, Davies, Geraint Rhys
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644328/
https://www.ncbi.nlm.nih.gov/pubmed/26566930
http://dx.doi.org/10.1186/s13063-015-1050-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644328/
https://www.ncbi.nlm.nih.gov/pubmed/26566930
http://dx.doi.org/10.1186/s13063-015-1050-1

Ejemplares similares